论文部分内容阅读
目的观察替吉奥胶囊联合同步放疗治疗晚期胃癌的临床疗效和安全性。方法将92例晚期胃癌患者随机分为对照组46例和试验组46例。对照组予以同步放疗,每周5次;试验组在对照组治疗的基础上,予以40 mg·m-2替吉奥,早晚各1次,口服,连服14 d后停药7 d。2组患者一个疗程21 d,共治疗2个疗程。比较2组患者的临床疗效和药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为67.39%(31例/46例)和45.65%(21例/46例),1年存活率分别为69.57%(32例/46例)和45.65%(21例/46例),差异均有统计学意义(均P<0.05)。试验组和对照组的Ⅲ~Ⅳ级恶心呕吐发生率分别为2.17%和15.22%,Ⅰ~Ⅱ级转氨酶升高发生率分别为17.39%和36.96%,Ⅲ~Ⅳ级白细胞减少发生率分别为10.87%和39.13%,差异均有统计学意义(均P<0.05)。结论替吉奥胶囊联合同步放疗治疗晚期胃癌的临床疗效显著,且安全性较好。
Objective To observe the clinical efficacy and safety of TIGO capsules combined with concurrent radiotherapy in the treatment of advanced gastric cancer. Methods Ninety-two patients with advanced gastric cancer were randomly divided into control group (46 cases) and experimental group (46 cases). The control group was treated with concurrent radiotherapy 5 times a week. On the basis of the control group, the experimental group was treated with 40 mg · m-2 of Gio, one morning and one night. Two groups of patients with a course of 21 d, a total of 2 courses of treatment. The clinical efficacy and adverse drug reactions in two groups were compared. Results After treatment, the total effective rates were 67.39% (31 cases / 46 cases) and 45.65% (21 cases / 46 cases) in the test group and the control group respectively. The 1-year survival rates were 69.57% (32 cases / 46 cases) And 45.65% (21 cases / 46 cases), respectively, with significant difference (all P <0.05). The incidences of grade Ⅲ ~ Ⅳ nausea and vomiting in trial group and control group were 2.17% and 15.22% respectively. The incidences of grade Ⅰ ~ Ⅱ transaminases were 17.39% and 36.96% respectively. The incidences of grade Ⅲ ~ Ⅳ leukopenia were 10.87 % And 39.13%, respectively (all P <0.05). Conclusion The treatment of advanced gastric cancer with Gio capsules combined with concurrent radiotherapy has significant clinical efficacy and good safety.